APGE Stock Overview
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Apogee Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.91 |
| 52 Week High | US$72.29 |
| 52 Week Low | US$14.19 |
| Beta | 0 |
| 1 Month Change | -21.74% |
| 3 Month Change | 49.78% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 139.80% |
Recent News & Updates
Shareholder Returns
| APGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.4% | 0.5% | -0.7% |
| 1Y | n/a | 1.2% | 22.8% |
Return vs Industry: Insufficient data to determine how APGE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how APGE performed against the US Market.
Price Volatility
| APGE volatility | |
|---|---|
| APGE Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APGE's share price has been volatile over the past 3 months.
Volatility Over Time: APGE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 91 | Michael Henderson | www.apogeetherapeutics.com |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. Fundamentals Summary
| APGE fundamental statistics | |
|---|---|
| Market cap | US$2.84b |
| Earnings (TTM) | -US$83.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-34.2x
P/E RatioIs APGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APGE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$83.99m |
| Earnings | -US$83.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APGE perform over the long term?
See historical performance and comparison